UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 28, 2023
AIMFINITY INVESTMENT CORP. I
(Exact name of registrant as specified in its charter)
| Cayman Islands |
|
001-41361 |
|
N/A |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of incorporation) |
|
|
|
Identification Number) |
221 W 9th St, PMB 235
Wilmington, Delaware 19801
(Address of principal executive offices)
(425) 365-2933
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☒ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act.
| Title of each class |
|
Trading Symbol |
|
Name of each exchange on which
registered |
| Units, consisting of one Class A ordinary share, $0.0001 par value, one Class 1 redeemable warrant and one-half of one Class 2 redeemable warrant |
|
AIMAU |
|
The Nasdaq Stock Market LLC |
| Class A ordinary shares, $0.0001 par value |
|
AIMA |
|
The Nasdaq Stock Market LLC |
| Class 1 redeemable warrants, each exercisable for one Class A ordinary share at an exercise price of $11.50 |
|
AIMAW |
|
The Nasdaq Stock Market LLC |
| Class 2 redeemable warrants, each exercisable for one Class A ordinary share at an exercise price of $11.50 |
|
AIMAW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.03 Creation
of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
As previously disclosed, on
July 27, 2023, Aimfinity Investment Corp. I, a Cayman Islands exempted company (“AIMA” or “Company”),
held an extraordinary general meeting (the “Shareholder Meeting”), where the shareholders of the Company approved to
amend the Company’s amended and restated memorandum and articles of associations (the “Charter”) to allow the
Company until July 28, 2023 to consummate an initial business combination and may elect to extend the period to consummate an initial
business combination up to nine times, each by an additional one-month period (each, a “Monthly Extension”), for a
total of up to nine months to April 28, 2024, by depositing to the Company’s trust account (the “Trust Account”)
the lesser of (i) $85,000 for all public shares and (ii) $0.04 for each public share for each one-month extension.
On
December 28, 2023, $85,000 (the “Sixth Monthly Extension Payment”) was deposited into the Trust Account for the public
shareholders, which enables the Company to extend the period of time it has to consummate its initial business combination by one month
from December 28, 2023 to January 28, 2024 (the “Sixth Extension”). This is the sixth of up to nine Monthly Extensions
permitted under the amended Charter.
In
connection with the Sixth Monthly Extension Payment, the Company issued an unsecured promissory note of $85,000 (the “Note”)
to I-Fa Chang, sole member and manager of Aimfinity Investment LLC, the sponsor of the company (the “Sponsor”), as
the Sponsor’s designee, to evidence the payments made for the Sixth Extension Payment.
The
Note bears no interest and is payable in full upon the earlier to occur of (i) the consummation of the Company’s business combination
(the “Business Combination”) or (ii) the date of expiry of the term of the Company (the “Maturity Date”).
The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date;
(ii) the commencement of a voluntary or involuntary bankruptcy action, (iii) the breach of the Company’s obligations thereunder;
(iv) any cross defaults; (v) an enforcement proceedings against the Company; and (vi) any unlawfulness and invalidity in connection with
the performance of the obligations thereunder, in which case the Note may be accelerated.
The
payee of the Note, Mr. Chang, has the right, but not the obligation, to convert the Promissory Note, in whole or in part, respectively,
into private units (the “Private Units”) of the Company, that are identical to the Private Units issued by the Company
in the private placement consummated simultaneously with the Company’s initial public offering, subject to certain exceptions, as
described in the final prospectus of the Company (File Number: 333-263874), by providing the Company with written notice of the intention
to convert at least two business days prior to the closing of the Business Combination. The number of Private Units to be received by
the Sponsor in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount
payable to the Sponsor by (y) $10.00.
The
issuance of the Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933,
as amended.
A
copy of the Note is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The disclosures
set forth in this Item 2.03 are intended to be summaries only and are qualified in their entirety by reference to the Note.
Item 3.02 Unregistered Sales of Equity Securities.
The information disclosed
under Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02 to the extent required herein.
The Private Units (and the underlying securities) issuable upon conversion of the Note, if any, (1) may not, subject to certain limited
exceptions, be transferable or salable by the Sponsor until the completion of the Company’s initial Business Combination and (2)
are entitled to registration rights.
Item 7.01 Regulation
FD Disclosure.
On December 28, 2023, the
Company issued a press release (the “Press Release”) announcing that the Sixth Extension. A copy of the Press Release
is furnished as Exhibit 99.1 hereto. The information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or
the Exchange Act of 1934, both as amended, except as expressly set forth by specific reference in such filing.
IMPORTANT NOTICES
Important Notice Regarding Forward-Looking
Statements
As disclosed previously on the Current Report
on Form 8-K filed on October 16, 2023, on October 13, 2023, AIMA entered into that certain Agreement and Plan of Merger (as may be amended,
supplemented or otherwise modified from time to time, the “Merger Agreement”), with Docter Inc., a Delaware corporation
(“Docter”), Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of AIMA
(“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of
Purchaser (“Merger Sub”), pursuant to AIMA will enter into a business combination with Docter that involves a reincorporation
merger and an acquisition merger.
This Current Report on Form 8-K contains certain
“forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both
as amended. Statements that are not historical facts, including statements about the pending transactions described above, and the parties’
perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the
proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction,
integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including
estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The
words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions
indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various
risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or
unknown, which could cause the actual results to vary materially from those indicated or anticipated.
Such risks and uncertainties include, but are
not limited to: (i) risks related to the expected timing and likelihood of completion of the pending business combination, including the
risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as
regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused
to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with
such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of
any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk
that there may be a material adverse change with respect to the financial position, performance, operations or prospects of Docter or
AIMA; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk
that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA’s securities;
(vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers
and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses
generally; (viii): risks relating to the medical device industry, including but not limited to governmental regulatory and enforcement
changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability
to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its
business partners. A further list and description of risks and uncertainties can be found in the prospectus filed on April 26, 2022 relating
to AIMA’s initial public offering (the “IPO Prospectus”), the annual report of AIMA on Form 10-K for the fiscal
year ended on December 31, 2022, filed on April 17, 2023 (the “Annual Report”), and in the registration statement on
Form S-4 or Form F-4/proxy statement that will be filed with the SEC by Purchaser in connection with the proposed transactions, and other
documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated
by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking
statements relate only to the date they were made, and AIMA, Docter and their subsidiaries undertake no obligation to update forward-looking
statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information and Where to Find It
In connection with the transaction described herein,
Purchaser will file relevant materials with the SEC including the registration statement on Form S-4 or Form F-4 and a proxy statement
(the “Registration Statement”). The proxy statement and a proxy card will be mailed to shareholders as of a
record date to be established for voting at the stockholders’ meeting of Parent shareholders relating to the proposed transactions.
Shareholders will also be able to obtain a copy of the Registration Statement and proxy statement without charge from Parent. The Registration
Statement and proxy statement, once available, may also be obtained without charge at the SEC’s website at www.sec.gov. INVESTORS
AND SECURITY HOLDERS OF PARENT ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT
DOCUMENTS IN CONNECTION WITH THE TRANSACTIONS THAT PARENT WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT PARENT, THE COMPANY AND THE TRANSACTIONS DESCRIBED HEREIN.
Participants in Solicitation
AIMA, Docter, and their respective directors,
executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of
AIMA’s ordinary shares stock in respect of the proposed transaction. Information about AIMA’s directors and executive officers
and their ownership of AIMA ordinary shares is set forth in the IPO Prospectus and the Annual Report. Other information regarding the
interests of the participants in the proxy solicitation will be included in the proxy statement pertaining to the proposed transaction
when it becomes available. These documents can be obtained free of charge from the sources indicated above.
No Offer or Solicitation
This Current Report on Form 8-K is not a proxy
statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described
above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of AIMA or Docter, nor shall there
be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except
by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
Aimfinity Investment Corp. I |
| |
|
|
| |
By: |
/s/ I-Fa Chang |
| |
Name: |
I-Fa Chang |
| |
Title: |
Chief Executive Officer |
| |
|
|
| Date: December 28, 2023 |
|
|
5
Exhibit 10.1
THIS PROMISSORY NOTE (“NOTE”) HAS
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT
ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
PROMISSORY NOTE
Principal Amount: US$85,000
Dated: December 28, 2023
New York, New York
FOR VALUE RECEIVED, Aimfinity Investment
Corp. I (the “Maker” or the “Company”) promises to pay to the order of I-Fa Chang, sole member and
manager of Aimfinity Investment LLC, or his assignees or successors in interest (the “Payee”), the principal sum
of Eighty-five Thousand Dollars (US$85,000), on the terms and conditions described below. All payments on this Note shall be made by wire
transfer of immediately available funds to such account as the Payee may from time to time designate by written notice in accordance with
the provisions of this note (the “Note”).
| 1. | Principal. The principal balance of this Note shall be
payable by the Maker to the Payee upon the date on which the Maker consummates a business combination or merger with a qualified target
company (as described in its Prospectus (as defined below)) (a “Business Combination”) or the date of expiry of the
term of the Maker, whichever is earlier (such date, the “Maturity Date”). The principal balance may be prepaid at
any time prior to the Maturity Date without penalty. Under no circumstances shall any individual, including but not limited to any officer,
director, employee or stockholder of the Maker, be obligated personally for any obligations or liabilities of the Maker hereunder. |
| 2. | Conversion Rights. The Payee has the right, but not the
obligation, to convert this Note, in whole or in part, into private units (the “Units”) of the Maker, each consisting
of one Class A ordinary share, one Class 1 redeemable warrant and one-half of one Class 2 redeemable warrant, as described in the Prospectus
of the Maker (File Number 333-263874) (the “Prospectus”), by providing the Maker with written notice of its intention
to convert this Note at least two business days prior to the closing of a Business Combination. The number of Units to be received by
the Payee in connection with such conversion shall be an amount determined by dividing (x) the sum of the outstanding principal amount
payable to such Payee by (y) $10.00. |
| (a) | Fractional Units. No fractional Units will be issued upon conversion of this Note. In lieu of any
fractional Units to which Payee would otherwise be entitled, the Maker will pay to Payee in cash the amount of the unconverted principal
balance of this Note that would otherwise be converted into such fractional Units. |
| (b) | Effect of Conversion. If the Maker timely receives notice of the Payee’s intention to convert
this Note at least two business days prior to the closing of a Business Combination, this Note shall be deemed to be converted on such
closing date. At its expense, the Maker will, upon receipt of such conversion notice, as soon as practicable after consummation of a Business
Combination, issue and deliver to Payee, at Payee’s address as requested by Payee in its conversion notice, a certificate or certificates
for the number of Units to which Payee is entitled upon such conversion (bearing such legends as are customary pursuant to applicable
state and federal securities laws), including a check payable to Payee for any cash amounts payable as a result of any fractional Units
as described herein. |
| 3. | Interest. This Note does not carry any interest on the
unpaid principal balance of this Note, provided, that, any overdue amounts shall accrue default interest at a rate per annum equal to
the interest rate which is the prevailing short term United States Treasury Bill rate, from the date on which such payment is due until
the day on which all sums due are received by the Payee. |
| 4. | Application of Payments. All payments shall be applied
first to payment in full of any costs incurred in the collection of any sum due under this Note, including but not limited to reasonable
attorney’s and auditor’s fees and expenses, then to the payment in full of any late charges, and finally to the reduction
of the unpaid principal balance of this Note. |
| 5. | Events of Default. The following shall constitute an
event of default (each, an “Event of Default”): |
| (a) | Failure to Make Required Payments. Failure by the Maker to pay the principal amount due pursuant
to this Note more than 5 business days of the Maturity Date. |
| (b) | Voluntary Bankruptcy, etc. The commencement by the Maker of a voluntary case under any applicable
bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession
by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of the Maker or for any substantial
part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of the Maker generally to pay
its debts as such debts become due, or the taking of corporate action by the Maker in furtherance of any of the foregoing. |
| (c) | Involuntary Bankruptcy, etc. The entry of a decree or order for relief by a court having jurisdiction
in the premises in respect of the Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing
a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of the Maker or for any substantial part of its
property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect
for a period of 60 consecutive days. |
| (d) | Breach of Other Obligations. The Maker fails to perform or comply with any one or more of its obligations
under this Note. |
| (e) | Cross Default. Any present or future indebtedness of the Maker in respect of moneys borrowed
or raised becomes (or becomes capable of being declared) due and payable prior to its stated maturity by reason of any event of default,
or any such indebtedness is not paid when due or, as the case may be, within any applicable grace period. |
| (f) | Enforcement Proceedings. A distress, attachment, execution or other legal process is levied or
enforced on or against any assets of the Maker which is not discharged or stayed within 30 days. |
| (g) | Unlawfulness and Invalidity. It is or becomes unlawful for the Maker to perform any of its obligations
under this Note, or any obligations of the Maker under this Note are not or cease to be legal, valid, binding or enforceable. |
| (a) | Upon the occurrence of an Event of Default specified in Section 5(a) and 5(d) hereof, the Payee may, by
written notice to the Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note,
and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice
of any kind, all of which are hereby expressly waived, notwithstanding anything contained herein or in the documents evidencing the same
to the contrary. |
| (b) | Upon the occurrence of an Event of Default specified in Sections 5(b), 5(c), 5(e), 5(f) and 5(g) hereof,
the unpaid principal balance of this Note, and all other sums payable with regard to this Note hereunder, shall automatically and immediately
become due and payable, in all cases without any action on the part of the Payee. |
| 7. | Taxes. The Maker will pay all amounts due hereunder free
and clear of and without reduction for any taxes, levies, imposts, deductions, withholding or charges imposed or levied by any governmental
authority or any political subdivision or taxing authority thereof with respect thereto (“Taxes”). The Maker will
pay on behalf of the Payee all such Taxes so imposed or levied and any additional amounts as may be necessary so that the net payment
of principal and any interest on this Note received by the Payee after payment of all such Taxes shall be not less than the full amount
provided hereunder. |
| 8. | Waivers. The Maker and all endorsers and guarantors of,
and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to
the Note, all errors, defects and imperfections in any proceedings instituted by the Payee under the terms of this Note, and all benefits
that might accrue to the Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds
arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption
from civil process, or extension of time for payment; and the Maker agrees that any real estate that may be levied upon pursuant to a
judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any
order desired by the Payee. |
| 9. | Unconditional Liability. The Maker hereby waives all
notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that
its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by
any indulgence, extension of time, renewal, waiver or modification granted or consented to by the Payee, and consents to any and all
extensions of time, renewals, waivers, or modifications that may be granted by the Payee with respect to the payment or other provisions
of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to the Maker
or affecting the Maker’s liability hereunder. For the purpose of this Note, “business day” shall mean a day (other
than a Saturday, Sunday or public holiday) on which banks are open in China and New York for general banking business. |
| 10. | Notices. All notices, statements or other documents which
are required or contemplated by this Note shall be made in writing and delivered: (i) personally or sent by first class registered or
certified mail, overnight courier service to the address most recently provided in writing to such party or such other address as may
be designated in writing by such party, (ii) by fax to the number most recently provided to such party or such other fax number as may
be designated in writing by such party, or (iii) by email, to the email address most recently provided to such party or such other email
address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been
given on (a) the day of delivery, if delivered personally, (b) only if the receipt is acknowledged, the day after such receipt, if sent
by fax or email, (c) the business day after delivery to an overnight courier service, if sent by an overnight courier service, or (d)
5 days after mailing if sent by first class registered or certified mail. |
| 11. | Construction. This Note shall be construed and enforced
in accordance with the laws of New York, without regard to conflict of law provisions thereof. |
| 12. | Severability. Any provision contained in this Note which
is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or
unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction
shall not invalidate or render unenforceable such provision in any other jurisdiction. The Payee hereby waives any and all right, title,
interest or claim of any kind (“Claim”) in or to any amounts contained in the trust account deriving from the proceeds
of the IPO conducted by the Maker and the proceeds of the sale of securities in a private placement (if any) prior to the effectiveness
of the IPO, as described in greater detail in the Prospectus filed with the Securities and Exchange Commission in connection with the
IPO (the “Trust Account Funds”), and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for
any Claim from the Trust Account Funds or any distribution therefrom for any reason whatsoever. If Maker does not consummate the Business
Combination, this Note shall be repaid only from amounts other than Trust Account Funds, if any. |
| 13. | Amendment; Waiver. Any amendment hereto or waiver of
any provision hereof may be made with, and only with, the written consent of the Maker and the Payee. |
| 14. | Assignment. This Note shall be binding upon the Maker
and its successors and assigns and is for the benefit of the Payee and its successors and assigns, except that the Maker may not assign
or otherwise transfer its rights or obligations under this Note. The Payee may at any time without the consent of or notice to the Maker
assign to one or more entities all or a portion of its rights under this Note. |
[signature page follows]
The Parties, intending to be legally bound hereby,
have caused this Note to be duly executed by the undersigned as of the day and year first above written.
MAKER:
Aimfinity Investment Corp. I
| By: |
/s/ I-Fa Chang |
|
| Name: |
I-Fa Chang |
|
| Title: |
CEO and Chairman |
|
PAYEE:
I-Fa Chang
[signature page to the promissory note]
5
Exhibit 99.1
Aimfinity
Investment Corp. I Announces Sixth Extension of the Deadline for an Initial Business Combination to January 28, 2024
Wilmington, Delaware, Dec. 28, 2023 (GLOBE
NEWSWIRE) -- Aimfinity Investment Corp. I (the “Company” or “AIMA”) (Nasdaq: AIMAU), a special
purpose acquisition company incorporated as a Cayman Islands exempted company, today announced that, in order to extend the date by which
the Company mush complete its initial business combination from December 28, 2023 to January 28, 2024, I-Fa Chang, sole member and
manager of the sponsor of the Company, has deposited into its trust account (the “Trust Account”) an aggregate of $85,000
(the “Monthly Extension Payment”).
Pursuant to the Company’s second amended &
restated memorandum and articles of association (“Current Charter”), effectively July 27, 2023, the Company may extend on
a monthly basis from July 28, 2023 until April 28, 2024 or such an earlier date as may be determined by its board to complete a business
combination by depositing the Monthly Extension Payment for each month into the Trust Account. This is the sixth of nine monthly extensions
of the Company.
About Aimfinity Investment Corp. I
Aimfinity Investment Corp. I is a blank check
company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one or more businesses or entities. The Company has not selected any business
combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any
business combination target with respect to an initial business combination with it. While the Company will not be limited to a particular
industry or geographic region in its identification and acquisition of a target company, it will not complete its initial business combination
with a target that is headquartered in China (including Hong Kong and Macau) or conducts a majority of its business in China (including
Hong Kong and Macau).
Additional Information and Where to Find It
As previously disclosed, on October 13, 2023,
the Company entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to
time, the “Merger Agreement”), by and between the Company, Docter Inc., a Delaware corporation (the “Company”),
Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of Parent (“Purchaser”),
and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser (“Merger Sub”),
pursuant to which the Company is proposing to enter into a business combination with Docter involving an reincorporation merger and an
acquisition merger. This press release does not contain all the information that should be considered concerning the proposed business
combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination.
AIMA’s stockholders and other interested persons are advised to read, when available, the proxy statement/prospectus and the amendments
thereto and other documents filed in connection with the proposed business combination, as these materials will contain important information
about AIMA, Purchaser or Docter, and the proposed business combination. When available, the proxy statement/prospectus and other relevant
materials for the proposed business combination will be mailed to stockholders of AIMA as of a record date to be established for voting
on the proposed business combination. Such stockholders will also be able to obtain copies of the proxy statement/prospectus and other
documents filed with the Securities and Exchange Commission (the “SEC”), without charge, once available, at the SEC’s
website at www.sec.gov, or by directing a request to AIMA’s principal office at 221 W 9th St, PMB 235 Wilmington, Delaware
19801.
Forward-Looking Statements
This press release contains certain “forward-looking
statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended. Statements
that are not historical facts, including statements about the pending transactions described herein, and the parties’ perspectives
and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction,
including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration
plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates
for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words “expect,”
“believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking
statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties,
assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause
the actual results to vary materially from those indicated or anticipated.
Such risks and uncertainties include, but are
not limited to: (i) risks related to the expected timing and likelihood of completion of the pending business combination, including the
risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as
regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused
to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with
such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of
any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk
that there may be a material adverse change with respect to the financial position, performance, operations or prospects of AIMA or Docter;
(v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that
any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA’s securities; (vii)
the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers
and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses
generally; (viii): risks relating to the medical device industry, including but not limited to governmental regulatory and enforcement
changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability
to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its
business partners.
A further list and description of risks and uncertainties
can be found in the prospectus filed on April 26, 2022 relating to AIMA’s initial public offering, the annual report of AIMA on
Form 10-K for the fiscal year ended on December 31, 2022, filed on April 17, 2023, and in the Registration Statement/proxy statement that
will be filed with the SEC by AIMA and/or its affiliates in connection with the proposed transactions, and other documents that the parties
may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking
statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements
relate only to the date they were made, and Aimfinity, Docter, and their subsidiaries undertake no obligation to update forward-looking
statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
No Offer or Solicitation
This press release is not a proxy statement or
solicitation of a proxy, consent or authorization with respect to any securities or in respect of any potential transaction and does not
constitute an offer to sell or a solicitation of an offer to buy any securities of AIMA, Purchaser or Docter, nor shall there be any sale
of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus
meeting the requirements of the Securities Act.
Participants in the Solicitation
AIMA, Docter, and their respective directors,
executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation
of proxies of AIMA’s shareholders in connection with the proposed transaction. Information regarding the persons who may, under
SEC rules, be deemed participants in the solicitation of AIMA’s shareholders in connection with the proposed business combination
will be set forth in the proxy statement/prospectus on Form F-4 to be filed with the SEC.
Contact Information:
Aimfinity Investment Corp. I
I-Fa Chang
Chief Executive Officer
221 W 9th St, PMB 235
Wilmington, Delaware 19801
Aimfinity Investment Cor... (NASDAQ:AIMBU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aimfinity Investment Cor... (NASDAQ:AIMBU)
Historical Stock Chart
From Apr 2023 to Apr 2024
